A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1.

ABSTRACT: Ligands that can bind selectively to proteins with single amino-acid point mutations offer the potential to detect or treat an abnormal protein in the presence of the wild type (WT). However, it is difficult to develop a selective ligand if the point mutation is not associated with an addressable location, such as a binding pocket. Here we report an all-chemical synthetic epitope-targeting strategy that we used to discover a 5-mer peptide with selectivity for the E17K-transforming point mutation in the pleckstrin homology domain of the Akt1 oncoprotein. A fragment of Akt1 that contained the E17K mutation and an I19[propargylglycine] substitution was synthesized to form an addressable synthetic epitope. Azide-presenting peptides that clicked covalently onto this alkyne-presenting epitope we

SUBMITTER: Deyle KM 

PROVIDER: S-EPMC4408887 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature